Product Description
Arbaclofen placarbil is a novel transported prodrug of the pharmacologically active R-isomer of baclofen designed to be absorbed throughout the intestine by both passive and active mechanisms via the monocarboxylate type 1 transporter. Arbaclofen placarbil is rapidly converted to R-baclofen in human and animal tissues in vitro.
Mechanisms of Action: GABA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: XenoPort, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Multiple Sclerosis
Phase 2: Back Pain|Gastroesophageal Reflux|Bile Reflux|Esophagitis, Peptic|Spinal Cord Injuries|Muscle Spasticity|Alcoholism
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03058237 |
INDV-AP-102 | P1 |
Completed |
Healthy Volunteers |
2017-07-05 |
2019-03-21 |
||
NCT02511886 |
RB-US-14-0001 | P2 |
Completed |
Alcoholism |
2016-01-01 |
2019-03-20 |
Treatments |
|
NCT00978016 |
XP-B-078 | P2 |
Completed |
Gastroesophageal Reflux|Esophagitis, Peptic |
2010-12-01 |
2021-02-22 |
Primary Endpoints|Treatments |
|
NCT00817986 |
XP-B-083 | P2 |
Completed |
Back Pain |
2009-07-01 |
2021-02-22 |
Primary Endpoints|Treatments |
|
NCT00557973 |
XP-B-065 | P2 |
Completed |
Muscle Spasticity|Spinal Cord Injuries |
2009-04-01 |
2021-02-22 |
Primary Endpoints |
|
NCT00557401 |
XP-B-057 | P2 |
Completed |
Gastroesophageal Reflux |
2008-09-01 |
2021-02-22 |
Primary Endpoints|Treatments |
|
NCT00838396 |
XP-B-049 | P2 |
Completed |
Gastroesophageal Reflux|Bile Reflux |
2006-08-01 |
2019-03-18 |
Treatments |
|
NCT01359566 |
XP-B-089 | P3 |
Completed |
Multiple Sclerosis |
2013-02-01 |
2021-02-22 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|